P F Thall

发表

Practical Bayesian guidelines for phase IIB clinical trials.

P F Thall, R Simon, P. Thall, 1994, Biometrics.

Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials.

P F Thall, H G Sung, H. Sung, 1998, Statistics in medicine.

Optimal two-stage designs for clinical trials with binary response.

P F Thall, R Simon, S S Ellenberg, 1988, Statistics in medicine.

Decision‐Theoretic Designs for Pre‐Phase II Screening Trials in Oncology

N Stallard, P F Thall, P. Thall, 2001, Biometrics.

A Bayesian approach to establishing sample size and monitoring criteria for phase II clinical trials.

P F Thall, R Simon, P. Thall, 1994, Controlled clinical trials.

Recent developments in the design of phase II clinical trials.

P F Thall, P. Thall, R. Simon, 1995, Cancer treatment and research.

Maximum Tolerated Dose of Nalmefene in Patients Receiving Epidural Fentanyl and Dilute Bupivacaine for Postoperative Analgesia

P F Thall, P. Thall, T B Dougherty, 2000, Anesthesiology.

Distribution-free confidence intervals for a parameter of Wilcoxon-Mann-Whitney type for ordered categories and progressive censoring.

P F Thall, P. Thall, M. Halperin, 1989, Biometrics.

Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.

P F Thall, P. Thall, E. Estey, 1999, Blood.

Practical model-based dose-finding in phase I clinical trials: Methods based on toxicity

P F Thall, P. Thall, S.-J. Lee, 2003, International Journal of Gynecologic Cancer.

Accrual strategies for phase I trials with delayed patient outcome.

P F Thall, P. Thall, E. Estey, 1999, Statistics in medicine.

Decision Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes

J Whitehead, N Stallard, P F Thall, 1999, Biometrics.

Semiparametric regression analysis for recurrent event interval counts.

P F Thall, P. Thall, J. Staniswalis, 1997, Biometrics.

Assessment of stratum-covariate interactions in Cox's proportional hazards regression model.

J M Lachin, P F Thall, P. Thall, 1986, Statistics in medicine.

A two-stage design for choosing among several experimental treatments and a control in clinical trials.

P F Thall, R Simon, S S Ellenberg, 1989, Biometrics.

New statistical strategy for monitoring safety and efficacy in single-arm clinical trials.

P F Thall, P. Thall, E. Estey, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment Comparisons Based on Two‐Dimensional Safety and Efficacy Alternatives in Oncology Trials

P F Thall, P. Thall, S C Cheng, 1999, Biometrics.

Phase I–II clinical trial design: a state-of-the-art paradigm for dose finding

P F Thall, P. Thall, M. Gilbert, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

A Bayesian strategy for screening cancer treatments prior to phase II clinical evaluation.

P F Thall, P. Thall, E. Estey, 1993, Statistics in medicine.

An optimal three-stage design for phase II clinical trials.

P F Thall, P. Thall, E. Gehan, 1994, Statistics in medicine.

Mixed Poisson likelihood regression models for longitudinal interval count data.

P F Thall, P. Thall, Peter F. Thall, 1988, Biometrics.

A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials.

P F Thall, P. Thall, K. E. Russell, 1998, Biometrics.

Optimal two-stage designs for clinical trials based on safety and efficacy.

P F Thall, S C Cheng, 2001, Statistics in medicine.

New designs for the selection of treatments to be tested in randomized clinical trials.

P F Thall, R Simon, S S Ellenberg, 1994, Statistics in medicine.